Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ScGET-seq profile of patient derived organoids from colorectal cancer samples

ABSTRACT: scGET-seq profile of patient derived organoids from colorectal cancer samples

PROVIDER: PRJEB64133 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

scGET-seq profile of patient derived organoids from colorectal cancer samples

Project description:scGET-seq profile of patient derived organoids from colorectal cancer samples

| PRJEB64005 | ENA

scGET-seq profile of patient derived organoids from colorectal cancer samples

Project description:One patient-derived organoids from liver metastasis of CRC samples were profiled by scGET-seq to analyze their genomic composition

2024-06-03 | E-MTAB-13126 | biostudies-arrayexpress

scGET-seq profile of patient derived organoids

Project description:Two patient-derived organoids from liver metastasis of CRC samples were profiled by scGET-seq to analyze their genomic composition

2021-08-17 | E-MTAB-10219 | biostudies-arrayexpress

Transcriptomic profiling of patient-derived endometrial cancer organoids (Berg HF)

Project description:Patient-derived endometrial cancer organoids. The data was used to compare gene expression profile between organoids, and to explore whether an organoid-derived gene signature could predict disease outcomes in independent patient cohorts.

2021-07-16 | E-MTAB-10664 | biostudies-arrayexpress

Expression data of cultured organoids derived from human colorectal cancer.

Project description:We analyzed gene expression of 3 lines of patient-derived colorectal cancer organoids.

2022-01-05 | GSE184732 | GEO

Expression data from CRC patient-derived organoids

Project description:Colorectal cancer (CRC) is a commonly occurring cancer worldwide. Metastasis and recurrence are the major causes of cancer-related death. CRC progression is a multistep process, and extensive efforts have been made to identify the genomic and transcriptomic alterations that occur during this process. However, whether primary tumors and metastatic lesions possess distinct biological features remains unclear. We established 74 patient-derived organoids (PDOs) from primary tumors and patient-matched metastatic and recurrent lesions.

2021-04-01 | GSE128213 | GEO

Single-cell RNA-seq analysis of patient derived organoids from colorectal cancers

Project description:Single-cell RNA-seq analysis of patient derived organoids from colorectal cancers

| PRJEB103949 | ENA

Expression data of cultured organoids derived from human colorectal tumors and normal samples.

Project description:We analyzed gene expression of 58 line patinet-derived colorectal tumors and normal organoids.

2016-05-26 | GSE74843 | GEO

Patient-derived Colorectal Cancer Organoids Enable Functional Prioritization of Molecular Tumor Board-Recommended Therapies

Project description:Patient-derived tumor organoids are clinically relevant ex vivo models that preserve key molecular and functional characteristics of the original tumor. The Freeze-O Organoid Biobank at the University Medical Center Freiburg is an integrated and translational platform to support Molecular Tumor Board-guided precision oncology by facilitating functional PDTO-based drug test. Informing personalized treatment strategies is often limited by the availability, quality, and quantity of patient-derived material. A major challenge is to provide clinically actionable information in time to inform treatment decisions, in particular for patients with metastatic disease. Here, we demonstrate rapid PDTO establishment from a lung metastasis of a patient with metastatic colorectal cancer. This enabled patient-specific drug tests and whole exome sequencing, which had not been feasible from the initial patient material. Using these PDTOs, we screened ten clinically relevant drugs, mainly targeting the ERK pathway based on the identified KRASG12V mutation. Single, combination, and long-term treatment assays revealed a patient-specific treatment rationale for vertical EGFR/HER-MEK1/2 inhibition using Lapatinib and Trametinib. These findings were presented to the Molecular Tumor Board; however, the patient succumbed to the severity of metastatic colorectal cancer. Earlier and routine integration of organoid-based drug testing into MTB processes could help identify personalized treatment strategies more efficiently. In particular, patients with severe metastatic cancer should be enrolled early enough to provide decisive information in a clinically actionable time frame.

2026-09-01 | GSE343714 | GEO

Characterization of patient-derived liver organoids

Project description:Characterization of patient-derived liver organoids

| PRJNA1516571 | ENA